Open company graph database — free web & API
Login

Perseus Proteomics Inc.

株式会社ペルセウスプロテオミクス
Ticker
Listed market
TYO
Country
Japan
Employees (consolidated)
34
Related companies
8
§01

Basic information

BASIC
Head office
3rd Floor, A.i.Nihombashi EAST, 30-1 Nihonbashi-Hakozakicho, Chuo-ku, Tokyo 103-0015, Japan
Chief executive
Takuya Yokokawa
Capital
751,000,000  (7 100 million)
Employees (non-consolidated)
35 people
Employees (consolidated)
34 people
Start date
2001-02-01
End date
§02

Websites

1 DOMAINS
§03

Business

6
Antibody research supportSales of antibodies and reagentsDrug discovery (development of antibody therapeutics)Drug discoveryPTX3 measurement kitAntibody screening and production using a VHH antibody library
§04

Related companies

8 COMPANIES
Company name Group Parent Subsidiary Customer Supplier Alliance Bank Shareholder
富士フイルム株式会社
Group Parent
RD Systems Inc.
Supplier
Shiai Audit Corporation
Supplier
Chugai Pharmaceutical Co., Ltd.
Alliance
New Energy and Industrial Technology Development Organization
Alliance
JST
Alliance
AMED
Alliance
Mitsubishi UFJ Trust and Banking Corporation
Names without a link are companies not yet registered in OpenBizGraph
§05

Network

NETWORK
Drag to move · click to open
§06

History

132 EVENTS

Date of establishment: February 1, 2001Sources

February 2001: The company was established in Bunkyo-ku, TokyoSources

Established in February 2001.Sources

February 2001: Perseus Proteomics is established in Bunkyo-ku, Tokyo.Sources

Established : Feb. 1, 2001Sources

October 2002: Began sales of anti-nuclear receptor antibodies as research reagentsSources

October 2002: A number of anti-nuclear receptor monoclonal antibodies are released as research reagents.Sources

Began selling antibodies as research reagents.Sources

A number of anti-nuclear receptor monoclonal antibodies are released as research reagents.Sources

October 2002: Began selling antibodies as research reagents.Sources

April 2003: Participated in the Nanobiotechnology Project for Protein Interaction Analysis of the New Energy and Industrial Technology Development Organization (NEDO)Sources

April 2003: The company joins the “Protein Interaction Analysis Nano-biochip Project” sponsored by NEDO.Sources

Participated in the New Energy and Industrial Technology Development Organization (NEDO) “Protein Interaction Analysis Nanobiochip Project”Sources

The company joins the “Protein Interaction Analysis Nano-biochip Project” sponsored by the New Energy and Industrial Technology Development Organization (NEDO) of the Ministry of Economy, Trade and Industry.Sources

July 2003: Moved the head office to Shibuya-ku, TokyoSources

July 2003: The company relocates head office to Shibuya-ku, Tokyo.Sources

Moved the head office to Shibuya-ku, TokyoSources

The company relocates head office to Shibuya-ku, Tokyo.Sources

July 2003: Relocated the head office to Shibuya-ku, Tokyo.Sources

August 2004: Signed a sales agency agreement with R&D Systems, Inc. for sales of research reagents in the United States, and began sales worldwideSources

August 2004: The company signs a distributorship agreement with R&D Systems Inc. for the distribution of research reagents in the US and initiates global sales.Sources

Entered into a distributor agreement with R&D Systems, Inc. for the sale of research reagents and began sales worldwideSources

The company signs a distributorship agreement with R&D Systems Inc. for the distribution of its research reagents in the United States and initiates global sales.Sources

August 2004: Entered into a distributorship agreement with R&D Systems Inc. for the sale of research reagents and began sales worldwide.Sources

September 2004: Moved the head office to Meguro-ku, TokyoSources

September 2004: The company relocates head office to Meguro-ku, Tokyo.Sources

Moved the head office to Meguro-ku, TokyoSources

The company relocates head office to Meguro-ku, Tokyo.Sources

September 2004: Relocated the head office to Meguro-ku, Tokyo.Sources

September 2005: Completed a full lineup of antibodies against all 48 nuclear receptorsSources

September 2005: The complete lineup of antibodies targeting all 48 nuclear receptors is presented.Sources

Began sales of antibodies against all 48 nuclear receptorsSources

The complete lineup of antibodies that target all 48 nuclear receptors is presented.Sources

September 2005: Began selling antibodies against all 48 nuclear receptors.Sources

September 2006: Signed an agreement with Chugai Pharmaceutical Co., Ltd. concerning the transfer of rights to obtain patents and other rights relating to the anti-glypican 3 antibody “anti-liver cancer antibody (PPMX-T001)” (agreement expired in June 2022)Sources

September 2006: The company signs an agreement with Chugai Pharmaceutical for the transfer of rights for the therapeutic use of the anti-glypican 3 antibody.Sources

Entered into an agreement with Chugai Pharmaceutical Co., Ltd. to transfer rights, including the right to obtain patents, relating to a glypican-3 antibody (PPMX-T001)Sources

The company signs an agreement with Chugai Pharmaceutical Co., Ltd. for the transfer of right for the therapeutic use of the anti-glypican 3 antibody “anti-hepatocarcinoma antibody (PPMX-T001).”Sources

September 2006: Entered into an agreement with Chugai Pharmaceutical Co., Ltd. to transfer rights, including the right to obtain patents, relating to a glypican 3 antibody (PPMX-T001).Sources

September 2008: Began sales of the research reagent “PTX3 ELISA Kit”Sources

September 2008: The research reagent “PTX3 ELISA kit” is released.Sources

Began sales of the research reagent “PTX3 ELISA Kit”Sources

The research reagent “PTX3 ELISA kit” is released.Sources

September 2008: Began selling the "PTX3 ELISA Kit" research reagent.Sources

November 2008: Phase I clinical trial of the anti-glypican 3 antibody “liver cancer therapeutic” began in the United States (PPMX-T001)Sources

November 2008: A phase I clinical trial of the anti-glypican 3 antibody begins in the United States.Sources

Phase I clinical trial of the glypican-3 antibody began in the United States (PPMX-T001)Sources

A phase I clinical trial of the anti-glypican 3 antibody “anti-hepatocarcinoma antibody (PPMX-T001)” begins in the United States.Sources

November 2008: A phase I trial of the glypican 3 antibody began in the United States (PPMX-T001).Sources

FUJIFILM Corporation became the parent company through a shareholder allotment capital increaseSources

January 2009: Fujifilm Corporation increases its capital in Perseus Proteomics by acquiring 76.68% of shares, becoming the parent company.Sources

FUJIFILM Corporation became the parent company by acquiring 76.68% of the Company’s shares through a third-party allotmentSources

Through shareholder allocation, FUJIFILM Corporation increases its capital in Perseus Proteomics by acquiring 76.68% of the issued shares to become the parent company.Sources

January 2009: FUJIFILM Corporation acquired 76.68% of the Company's shares through a third-party allotment and became its parent company.Sources

January 2011: Licensed the radiolabeled antibody anticancer drug (PPMX-T002) to FUJIFILM CorporationSources

January 2011: A radioisotope-labeled antibody (PPMX-T002) is licensed to Fujifilm Corporation.Sources

Licensed a radioisotope-labeled cadherin-3 antibody to FUJIFILM Corporation (PPMX-T002)Sources

A radioisotope (RI)-labeled antibody (PPMX-T002), an anticancer drug, is licensed to FUJIFILM Corporation.Sources

January 2011: Licensed a radioisotope (Note 2)-labeled cadherin 3 antibody to FUJIFILM Corporation (PPMX-T002).Sources

December 2014: A treatment for adult T-cell leukemia using an anti-transferrin receptor antibody (PPMX-T003) was selected as a project under the Practical Application Challenge Type (Drug Discovery and Development) of the Japan Science and Technology Agency (JST) Adaptable and Seamless Technology Transfer Program through Target-driven R&D (A-STEP)Sources

December 2014: A drug based on an anti-transferrin receptor antibody (PPMX-T003) is selected for practical application development under JST's A-STEP program.Sources

The transferrin receptor antibody was selected for a project under the Practical Application Challenge Type (Drug Development) of the Japan Science and Technology Agency (JST)’s Adaptable and Seamless Technology Transfer Program through Target-driven R&D (A-STEP) (PPMX-T003)Sources

A drug for the treatment of adult T-cell leukemia based on an anti-transferrin receptor antibody (PPMX-T003) is selected by the Adaptable and Seamless Technology Transfer Program through Target-driven R&D (A-STEP) program of the Japan Science and Technology Agency (JST) for the practical application development (drug development) division.Sources

December 2014: The transferrin receptor antibody was selected for the drug development project under the Practical Application Challenge Type (Drug Development) of the Japan Science and Technology Agency (JST)'s Adaptable and Seamless Technology Transfer Program through Target-driven R&D (PPMX-T003).Sources

September 2015: Out-licensed the antibody-drug conjugate (PPMX-T004) to FUJIFILM Corporation.Sources

September 2015: Antibody Drug Conjugate (PPMX-T004) is licensed to Fujifilm Corporation.Sources

Licensed a drug-conjugated cadherin-3 antibody to FUJIFILM Corporation (PPMX-T004)Sources

Antibody Drug Conjugate (PPMX-T004) is licensed to FUJIFILM Corporation.Sources

September 2015: Licensed the drug-conjugated cadherin 3 antibody to FUJIFILM Corporation (PPMX-T004).Sources

January 2016: A Phase I trial in the United States began for PPMX-T002, an anticancer drug consisting of a radioisotope (RI)-labeled antibody drug.Sources

January 2016: A phase I clinical trial of the radioisotope-labeled antibody (PPMX-T002) begins in the United States.Sources

Phase I clinical trial of a radioisotope-labeled cadherin-3 antibody began in the United States (PPMX-T002)Sources

A phase I clinical trial of the radioisotope (RI)-labeled antibody (PPMX-T002) as an anticancer drug begins in the United States.Sources

January 2016: A Phase I trial of the radioisotope-labeled cadherin 3 antibody began in the United States (PPMX-T002).Sources

March 2018: FUJIFILM Corporation's ownership percentage in the Company decreased following a shareholder allotment of new shares, and it became an "other affiliated company" of the Company.Sources

March 2018: Fujifilm reduces its shareholding percentage to 48.62% and becomes an 'other associated company'.Sources

FUJIFILM Corporation’s shareholding in the Company fell to 48.62% through a third-party allotment, making it an other affiliated company of the CompanySources

After allocation of new shares to a third party, FUJIFILM Corporation reduces its percentage of shares of the Company to 48.62% and becomes an 'other associated company'.Sources

March 2018: Through a third-party allotment of shares, FUJIFILM Corporation's ownership stake in the Company reached 48.62%, making it an affiliate of the Company.Sources

January 2019: Opened the Nagoya Laboratory in Chikusa-ku, Nagoya, Aichi Prefecture, to maintain and advance phage display technology and promote research and development of antibody drugs.Sources

January 2019: The company opens the Nagoya Laboratory in Chikusa-ku, Nagoya.Sources

Opened the Nagoya Laboratory in Chikusa-ku, Nagoya, Aichi Prefecture, to maintain and develop phage display technology and promote research and development of antibody drugsSources

The company opens the Nagoya Laboratory in Chikusa-ku, Nagoya, Aichi Prefecture, for the maintenance and development of phage display technologies and the promotion of research and development of antibody drugs.Sources

November 2019: The Company began a Phase I trial in Japan of an anticancer drug using an anti-transferrin receptor antibody (PPMX-T003).Sources

November 2019: A phase I clinical trial of the anti-transferrin receptor antibody (PPMX-T003) begins in Japan.Sources

Phase I clinical trial in Japan of the transferrin receptor antibody for polycythemia vera, the Company’s first in-house clinical trial, began (PPMX-T003)Sources

A phase I clinical trial of the anti-transferrin receptor antibody (PPMX-T003) as an anticancer drug begins in Japan.Sources

November 2019: A Phase I trial in patients with polycythemia vera of the transferrin receptor antibody, the Company's first company-sponsored clinical trial, began in Japan (PPMX-T003).Sources

April 2020: A Phase I trial in Japan began for PPMX-T002, an anticancer drug consisting of a radioisotope (RI)-labeled antibody drug.Sources

April 2020: A phase I clinical trial of the radioisotope-labeled antibody (PPMX-T002) begins in Japan.Sources

Phase I clinical trial in Japan of an anticancer drug using a radioisotope-labeled cadherin-3 antibody began (PPMX-T002)Sources

A phase I clinical trial of the radioisotope (RI)-labeled antibody (PPMX-T002) as an anticancer drug begins in Japan.Sources

April 2020: A Phase I trial in Japan began for the anticancer drug using a radioisotope-labeled cadherin 3 antibody (PPMX-T002).Sources

June 2021: Listed its shares on the Tokyo Stock Exchange Mothers market.Sources

June 2021: Shares of the company are listed on Mothers Market, TSE.Sources

Listed its shares on the Tokyo Stock Exchange Mothers marketSources

Shares of the Company are listed on Mothers Market, TSESources

March 2022: Research and development of PPMX-T003 for aggressive NK-cell leukemia was selected as a project under the Drug Discovery Support Promotion Program and the Pre-Practical-Application Support Program for Orphan Drug Designation of the Japan Agency for Medical Research and Development (AMED).Sources

March 2022: Terminated the license agreements with FUJIFILM Corporation for PPMX-T002 and PPMX-T004.Sources

March 2022: Research project on ANKL (PPMX-T003) is selected under the AMED Drug Discovery Promotion Program.Sources

March 2022: License agreement for PPMX-T002 and license & knowhow agreement for PPMX-T004 between Fujifilm are terminated.Sources

Research and development targeting aggressive natural killer-cell leukemia (ANKL) was selected as a project under the FY2022 Drug Discovery Support Promotion Program’s Practical Application Support Program for Drugs for Rare Diseases Prior to Designation, administered by the Japan Agency for Medical Research and Development (AMED) (PPMX-T003)Sources

Terminated the license agreements with FUJIFILM Corporation for PPMX-T002 and PPMX-T004Sources

Research and development project on ANKL (PPMX-T003) is selected as a project under the AMED Drug Discovery Promotion Program and Pre-designation Support Program for Orphan Drugs.Sources

License Agreement for PPMX-T002 and License & Knowhow Agreement for PPMX-T004 between FUJIFILM are terminated.Sources

March 2022: Research and development targeting aggressive NK-cell leukemia (ANKL) was selected for the FY2022 project under the Drug Discovery Support Promotion Program's Pre-designation Practical Application Support Program for Orphan Drugs of the Japan Agency for Medical Research and Development (AMED) (PPMX-T003).Sources

April 2022: Transferred from the Mothers market to the Growth market following the Tokyo Stock Exchange's restructuring of its market segments.Sources

April 2022: The listed market transitions from Mother Market to Growth Market due to market segmentation restructuring.Sources

Following the Tokyo Stock Exchange's review of its market segments, the company moved from the Mothers market to the Growth market.Sources

The listed market transitions from Mother Market to Growth Market, TSE due to market segmentation restructuring of TSE.Sources

September 2022: FUJIFILM Corporation ceased to be an "other affiliated company" of the Company.Sources

September 2022: Fujifilm Corporation's shareholding percentage reduces to 16.48%, no longer considered 'other associated company'.Sources

FUJIFILM Corporation ceased to be one of the Company's other affiliated companies.Sources

FUJIFILM Corporation is no longer "other associated company" due to reduction of its percentage of shares of the Company to 16.48%.Sources

September 2022: FUJIFILM Corporation ceased to be an affiliate of the Company.Sources

March 2023: The clinical trial notification for a physician-initiated Phase I/II trial of PPMX-T003 for aggressive NK-cell leukemia (ANKL) was approved.Sources

March 2023: Clinical Trial Notification of Investigator-led Phase I/II Clinical Trial for ANKL (PPMX-T003) is submitted and approved.Sources

A clinical trial notification was submitted and approved for a physician-initiated Phase I/II trial targeting ANKL (PPMX-T003).Sources

Clinical Trial Notification of Investigator-led Phase I/II Clinical Trial for ANKL is submitted and approved.(PPMX-T003).Sources

March 2023: A clinical trial notification was submitted and approved for a physician-initiated Phase I/II trial targeting ANKL (PPMX-T003).Sources

July 2023: Relocated its head office to Chuo-ku, Tokyo.Sources

July 2023: The company relocates head office to Chuo-ku, Tokyo.Sources

The head office relocated to Chuo-ku, Tokyo.Sources

The company relocates head office to Chuo-ku, Tokyo.Sources

July 2023: The head office relocated to Chuo-ku, Tokyo.Sources

February 2025: Research and development for ANKL was selected as a project under AMED's FY2025 Drug Discovery Support Promotion Program and Pre-Practical-Application Support Program for Orphan Drug Designation (PPMX-T003).Sources

February 2025: Research project on ANKL (PPMX-T003) is selected under the AMED Drug Discovery Promotion Program for FY2025.Sources

Research and development targeting ANKL was selected as a project under AMED's FY2025 Drug Discovery Support Promotion Program and Pre-Designation Support Program for Practical Application of Orphan Drugs (PPMX-T003).Sources

Research and development project on ANKL is selected as a project under the AMED Drug Discovery Promotion Program and Pre-designation Support Program for Orphan Drugs for FY2025 (PPMX-T003).Sources

The company began offering antibody research support for antibody screening and production using a VHH antibody library.Sources

Launch "VHH antibody library-based screening and production" to expand the Antibody Research Support ServiceSources

May 2025: Began offering antibody research support services for antibody screening and generation using a VHH antibody library.Sources

§07

News

0 ARTICLES

There is no news.

§08

Public records

GOV
National Tax Agency basic information1013201011111
Source: National Tax Agency Corporate Number Publication Site, basic three itemsSources
Trade name
株式会社ペルセウスプロテオミクス
Trade name (kana)
ペルセウスプロテオミクス
Name in English
Corporation type
301
Address
〒103-0015 東京都中央区日本橋箱崎町30番1号
Postal code
1030015
Prefecture code
13
City code
102
Address outside Japan
Prefecture in English
City in English
Address outside Japan in English
Corporate number assignment date
2015-10-05
Update date
2023-07-28
Change date
2023-07-24
Registry closure date
Reason for registry closure
Successor corporate number
Details of the change
Latest record
1
Excluded from search
0
Processing type
12
Correction type
0
Trade name image ID
Address image ID
Sequence number
1405536
METI gBizINFO1013201011111
Source: gBizINFO (Ministry of Economy, Trade and Industry)Sources
Corporate number
1013201011111
Trade name
株式会社ペルセウスプロテオミクス
Trade name (kana)
ペルセウスプロテオミクス
Trade name (alphabet)
Registry closure date
Reason for registry closure
Registered address
東京都中央区日本橋箱崎町30番1号
Postal code
1030015
Prefecture
東京都
Prefecture code
13
City or district
中央区
City code
102
Street address
日本橋箱崎町30番1号
Organisation type
301
Processing type
12
Correction type
0
Status
Representative
代表取締役社長執行役員  横川 拓哉
Capital
751161000
Employees
17
Employees (male)
6
Employees (female)
11
Business summary
創薬、研究開発
Website URL
https://www.ppmx.com/
Year founded
Business category
E:製造業
Date established
Unified government qualification - grade
Unified government qualification - business items
Update date
2023-07-28
Key information
1013201011111
§09

Sources & updates

SOURCES
↑